undamentalytics Newsletter

Doherty David T: insider trades

Chief financial officer at Surgery Partners, Inc. No open-market purchases and 18 sales not made under a pre-set plan, reported from March 2, 2022 to March 16, 2026.

What happened after Doherty David T’s sales?

After their sales, the shares moved −39.2% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Doherty David T: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 18 −7.7% −9.1% 67% 5 −1.40 0.23 No reliable evidence
Sales, 12 months after the report 16 −39.2% −36.8% 100% 4 −6.53 0.007 Some evidence: seller right
Sales, 12 months after the trade 16 −40.1% −37.3% 100% 4 −6.02 0.009 Some evidence: seller right

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Surgery Partners, Inc. SGRY Chief Financial Officer018March 2, 2022March 16, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
March 16, 2026March 16, 2026 SGRY Sale $110,838 +7.5%not yetnot yet
March 9, 2026March 6, 2026 SGRY Sale $201,704 −1.3%not yetnot yet
August 8, 2025August 8, 2025 SGRY Sale $1,110,814 −11.3%−55.5%−58.8%
March 13, 2025March 10, 2025 SGRY Sale $161,727 −10.0%−67.0%−65.1%
February 10, 2025February 7, 2025 SGRY Sale $349,346 −8.2%−53.7%−62.6%
March 15, 2024March 14, 2024 SGRY Sale $20,613 −15.4%−22.7%−25.6%
March 6, 2024March 4, 2024 SGRY Sale $104,048 −17.8%−30.6%−34.0%
February 14, 2024February 12, 2024 SGRY Sale $35,629 −29.4%−49.3%−49.7%
February 6, 2024February 2, 2024 SGRY Sale $73,538 −20.2%−43.9%−44.3%
September 1, 2023August 29, 2023 SGRY Sale $79,352 −0.8%−35.7%−36.3%
March 15, 2023March 13, 2023 SGRY Sale $104,029 +19.2%−46.3%−40.7%
March 6, 2023March 3, 2023 SGRY Sale $679,600 +12.8%−38.1%−37.6%
March 1, 2023February 27, 2023 SGRY Sale $144,682 +9.7%−37.9%−37.5%
February 15, 2023February 13, 2023 SGRY Sale $31,953 +1.7%−27.9%−23.1%
February 6, 2023February 2, 2023 SGRY Sale $69,897 +3.6%−24.7%−30.9%
March 17, 2022March 15, 2022 SGRY Sale $236,821 −29.1%−28.9%−31.2%
March 14, 2022March 11, 2022 SGRY Sale $20,563 −27.4%−31.2%−37.2%
March 2, 2022February 25, 2022 SGRY Sale $112,116 −22.8%−33.8%−27.7%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Doherty David T traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.